Texas Attorney General Files Suit Against Tylenol Makers Over Pregnancy Marketing Risks to Children

---

Full Story

Texas Attorney General Ken Paxton has initiated a lawsuit against Tylenol manufacturers, alleging deceptive promotion of the pain reliever to pregnant women despite known risks to fetal development. The complaint accuses the companies of prioritizing sales over safety disclosures, potentially linking the drug to autism and ADHD in offspring. This action invokes consumer protection statutes to demand accountability for misleading claims.

Acetaminophen, the active ingredient in Tylenol, has been a household staple since 1955, widely recommended for fever and pain relief across demographics. Recent studies, though not cited here, have prompted warnings from health bodies like the FDA on third-trimester use.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 31% | Right 40% | Center 26% | Unrated 3%

The Context

Paxton’s suit claims the firms concealed internal data on neurodevelopmental harms, violating state deceptive trade practices laws. Such allegations mirror national trends in pharmaceutical litigation, seeking damages and label reforms.

Pregnancy medication guidelines, established by organizations like the American College of Obstetricians and Gynecologists, stress weighing benefits against risks for any drug. This case spotlights evolving science on everyday remedies’ long-term impacts.

Proponents of the lawsuit hail it as a win for informed consent, empowering families with full risk knowledge to make health choices. Detractors argue it overreaches, potentially chilling legitimate medical advice and access to proven treatments.

The complaint details marketing campaigns that downplayed concerns, allegedly influencing obstetric prescribing patterns nationwide. Texas, with its robust AG powers under the Deceptive Trade Practices Act, leads in such consumer suits.

Judicial precedents in drug marketing cases, like those against opioids, set frameworks for proving intent and harm causation. Outcomes here could ripple to class actions in other states.

As discovery proceeds, expect scrutiny of corporate emails and trial data, illuminating decision-making on public communications. This transparency push aligns with broader calls for pharma accountability.